Dexcom
DXCMWhat is it worth to you? Move six assumptions and see what value per share you get, and where you stand against the price and other users.
At $82.52 (close on November 18) and with the other assumptions at their starting point, Dexcom's sales would need to grow 34.6% a year for ten years; over its last decade, the median was 26.2%. Value it with your own assumptions.
Its accounts, year by year
| Year end | Sales | Growth | Margin |
|---|---|---|---|
| 12/2015 | 402 | — | 6.4% |
| 12/2016 | 573 | 42.6% | 8.2% |
| 12/2017 | 718 | 25.3% | 8.9% |
| 12/2018 | 1,032 | 43.6% | −8.2% |
| 12/2019 | 1,476 | 43.1% | 16.6% |
| 12/2020 | 1,927 | 30.5% | 21.7% |
| 12/2021 | 2,448 | 27.1% | 15.5% |
| 12/2022 | 2,910 | 18.8% | 17.8% |
| 12/2023 | 3,622 | 24.5% | 20.7% |
| 12/2024 | 4,033 | 11.3% | 19.1% |
| 12/2025 | 4,662 | 15.6% | 23.0% |
Sales in millions of dollars. The margin is the operating margin before stock pay, as a percentage of sales. Each row is a fiscal year, by the month it ends. Source: the reports Dexcom files with the SEC, the US securities regulator; the latest is for the fiscal year ended December 31, 2025. See the report.
The model's starting point
- Sales growth, years 1 to 10: 18.8% a year.
- Sales growth after year 10: 2.5% a year.
- Operating margin, before stock pay: 20.7% of sales.
- Working capital needed to grow: $12.2 per $100 of new sales.
- Capital spending: 8.9% of sales.
- Stock pay to employees: 9.2% of sales.
- Discount rate, the same for every company: 10%.
These are the six assumptions the page starts with; each user moves them as they see fit.
Reference points
They come from its accounts and its share price, compared with the median of the companies on grinboss. They are not a recommendation.
For
- Its sales grew 27.8% a year on average over 10 years, from $0.4 billion to $4.7 billion; the median of grinboss companies is 6.6%.
- It sold more than the year before in 10 of the last 10 years.
- It has more cash than debt.
- Its margin has risen over these years, from 8% to 21%.
Against
- Its stock pay to employees is high: 9.2% of sales, more than the median (1.5%). That is a part of the company that stops belonging to the shareholders.
- It generated free cash flow in only 3 of the last 5 years.
- It is one of the smallest in grinboss: it sells $4.7 billion a year; the median is $15.1 billion.
- It needs to invest a lot: its capital spending takes 8.9% of its sales every year, more than the median (3.3%).
Next results: January 11, 2027.
Other companies in its sector (Health Care)
Edwards Lifesciences (EW) · GE HealthCare (GEHC) · Gilead Sciences (GILD) · HCA Healthcare (HCA) · Henry Schein (HSIC) · Idexx Laboratories (IDXX) · Illumina, Inc. (ILMN) · Incyte (INCY) · All companies
Loading the model…